Muñoz-Cano Rosa M, Casas-Saucedo Rocio, Valero Santiago Antonio, Bobolea Irina, Ribó Paula, Mullol Joaquim
Allergy Section, Pheumology & Allergy Department, Hospital Clinic, Barcelona, 08036 Catalonia, Spain.
Clinical & Experimental Respiratory Immunoallergy, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, 08036 Catalonia, Spain.
J Clin Med. 2019 Aug 29;8(9):1338. doi: 10.3390/jcm8091338.
Platelet-activating factor (PAF) is a lipid mediator involved in several allergic reactions. It is released from multiple cells of the immune system, such as eosinophils, neutrophils, and mast cells, and also exerts its effect on most of them upon specific binding to its receptor, becoming a pleiotropic mediator. PAF is considered a potential relevant mediator in allergic rhinitis, with a key role in nasal congestion and rhinorrhoea due to its effect on vascular permeability. Interestingly, despite its potential relevance as a therapeutic target, no specific PAF inhibitors have been studied in humans. However, rupatadine, a second-generation antihistamine with dual antihistamine and anti-PAF effects has shown promising results by both blocking nasal symptoms and inhibiting mast cell activation induced by PAF, in comparison to antihistamine receptor drugs. In conclusion, the inhibition of PAF may be an interesting approach in the treatment of allergic rhinitis as part of a global strategy directed at blocking as many relevant inflammatory mediators as possible.
血小板活化因子（PAF）是一种参与多种过敏反应的脂质介质。它从免疫系统的多种细胞中释放出来，如嗜酸性粒细胞、中性粒细胞和肥大细胞，并且在与受体特异性结合后也会对其中大多数细胞发挥作用，成为一种多效性介质。PAF被认为是变应性鼻炎中一种潜在的相关介质，因其对血管通透性的影响，在鼻充血和鼻漏中起关键作用。有趣的是，尽管其作为治疗靶点具有潜在相关性，但尚未在人体中研究过特异性PAF抑制剂。然而，卢帕他定是一种具有双重抗组胺和抗PAF作用的第二代抗组胺药，与抗组胺受体药物相比，通过阻断鼻部症状和抑制PAF诱导的肥大细胞活化，已显示出有前景的结果。总之，抑制PAF可能是作为旨在阻断尽可能多相关炎症介质的整体策略的一部分，用于治疗变应性鼻炎的一种有趣方法。
